• Celcuity Inc. has reported that its Phase 3 VIKTORIA-1 trial of gedatolisib in HR-positive, HER2-negative advanced breast cancer met its primary progression-free survival endpoint, while first-quarter 2026 results showed a wider net loss of US$52.84 million and basic loss per share of US$0.97.
• The company is reshaping its development plan by expanding the Phase 3 VIKTORIA-2 trial to cover both endocrine-resistant and endocrine-sensitive first-line patients and pursuing a patented subcutaneous formulation of gedatolisib that could support long-term, more convenient treatment.
• Next, we’ll examine how expanding VIKTORIA-2 into both endocrine-resistant and endocrine-sensitive populations may influence Celcuity’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Celcuity Investment Narrative Recap

To own Celcuity, you have to believe gedatolisib can convert its late stage breast cancer data into regulatory approval and real, usable treatment regimens, while the company manages steep, pre revenue losses. The latest update, expanding VIKTORIA 2 and filing a subcutaneous patent, supports the long term story but does not materially change the near term catalyst, which remains the upcoming FDA decision, or the key risk of continued high cash burn without offsetting revenue.

The most relevant recent development here is the VIKTORIA 2 protocol amendment, which now tests gedatolisib in both endocrine resistant and endocrine sensitive first line HR positive, HER2 negative advanced breast cancer. This broadens the potential treated population and ties directly into the central catalyst of turning gedatolisib into a platform therapy in breast cancer, while also increasing the importance of how efficiently Celcuity can execute larger, more complex Phase 3 studies over time.

But while the upside story is compelling, investors should also be aware that the combination of widening quarterly net losses and a heavily financed balance sheet could...

Celcuity's narrative projects $607.1 million revenue and $152.4 million earnings by 2029. This implies an earnings increase of about $315 million from -$162.7 million today.

Uncover how Celcuity's forecasts yield a $116.70 fair value, a 15% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming only about US$414.4 million of revenue and US$129.7 million of earnings by 2029, so if you worry about heavy financing and complex trial timelines, this new data might either challenge or reinforce that more cautious story depending on how you weigh the risks and rewards.

Explore 3 other fair value estimates on Celcuity - why the stock might be worth over 6x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Celcuity research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.